NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
CREXONT (carbidopa and levodopa) by Viatris (2) is dopa decarboxylase inhibitors [moa]. First approved in 2024.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CREXONT is an extended-release oral capsule combining carbidopa (a DOPA decarboxylase inhibitor) and levodopa for Parkinson's disease management. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa blocks peripheral conversion to enhance CNS delivery. This formulation addresses motor complications in established Parkinson's disease.
Growth15.5 years to LOE
As a newly approved product in growth phase with strong patent protection through 2041, the brand team will focus on market penetration and establishing formulary position against legacy carbidopa-levodopa competitors.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Career Relevance
CREXONT represents a growth-stage specialty pharmaceutical asset with long patent exclusivity and unmet market positioning in motor complication management. Career opportunities span brand management, reimbursement strategy, and specialty sales, with stable long-term employment prospects through 2040.
Brand Manager
Worked on CREXONT at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.